Core Viewpoint - Yifang Bio (688382.SH) reported a revenue of 19.16 million yuan for the first half of 2025, marking a year-on-year increase of 28.85%, while the net profit attributable to shareholders was a loss of 119.3 million yuan, an improvement from a loss of 214.0 million yuan in the same period last year [1][3]. Financial Performance - The company's revenue for the first half of 2025 was 19.16 million yuan, up from 14.87 million yuan in the previous year, reflecting a growth of 28.85% [3]. - The total profit for the period was a loss of 119.43 million yuan, compared to a loss of 214.22 million yuan in the same period last year [3]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was a loss of 129.02 million yuan, improving from a loss of 214.65 million yuan year-on-year [1][3]. - The net cash flow from operating activities was -107.25 million yuan, an improvement from -188.77 million yuan in the previous year [1][3]. Historical Context - Yifang Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 25, 2022, issuing 115 million shares at a price of 18.12 yuan per share [4]. - The total funds raised during the IPO amounted to 208.38 million yuan, with a net amount of 198.22 million yuan after expenses, which was 42.72 million yuan less than originally planned [4]. - The company reported a net loss of 240.20 million yuan for the fiscal year 2024, with a net loss of 250.14 million yuan when excluding non-recurring items, indicating a reduction in losses compared to the previous year [1][4]. Ownership Structure - The actual controllers of the company are YAOLIN WANG, YUEHENG JIANG, and XING DAI, all of whom hold American nationality [5].

Group 1 - The core viewpoint of the news is that Yifang Biotechnology has seen a significant increase in its stock price, rising by 5.03% to 36.99 CNY per share, with a trading volume of 388 million CNY and a turnover rate of 2.58%, resulting in a total market capitalization of 21.392 billion CNY [1] - Yifang Biotechnology, established on January 11, 2013, and listed on July 25, 2022, is primarily engaged in the research, production, and sales of innovative drugs, with 100% of its main business revenue coming from technology licensing and cooperation [1] Group 2 - From the perspective of fund holdings, one fund under Nuoan Fund has heavily invested in Yifang Biotechnology, specifically the Nuoan Selected Value Mixed A fund, which increased its holdings by 225,100 shares in the second quarter, bringing its total to 654,100 shares, accounting for 5.97% of the fund's net value, making it the seventh-largest holding [2] - The Nuoan Selected Value Mixed A fund, established on February 28, 2019, has a latest scale of 74.2367 million CNY, with a year-to-date return of 99.47% and a one-year return of 105.15%, ranking 58 out of 8,174 and 392 out of 7,981 respectively [2] - The fund manager, Tang Chen, has been in position for 2 years and 268 days, managing assets totaling 753 million CNY, with the best fund return during his tenure being 105.54% and the worst being 8.84% [2]

Summary of Key Points Core Viewpoint - On September 11, a total of 105 stocks were traded on the block trading platform, with a cumulative trading volume of 217 million shares and a total transaction value of 3.577 billion yuan, indicating active trading in the market [1]. Group 1: Top Block Trades - The highest transaction value was recorded by China Western Electric, with a single transaction amounting to 593 million yuan [1]. - Huatai Medical followed closely with a transaction value of 537 million yuan from one trade [1]. - Other notable stocks included Guangqi Technology, with a transaction value of 230 million yuan, and Huichuan Technology, with 129 million yuan [1]. Group 2: Stock Performance - China Western Electric saw a price increase of 0.78%, closing at 6.47 yuan, with a transaction price of 5.78 yuan, reflecting a discount of 10.66% [1]. - Huatai Medical's stock rose by 1.21%, closing at 309.53 yuan, with a transaction price of 248.20 yuan, showing a discount of 19.81% [1]. - Other stocks with significant price movements included Guangqi Technology (+3.21%), Huichuan Technology (+1.48%), and Tongcheng New Materials (+3.29%) [1].

Group 1 - The core point of the article highlights that Yifang Bio-U executed two block trades on September 11, totaling 2.07 million shares with a transaction value of 62.41 million yuan, at a price of 30.15 yuan, which represents a discount of 14.40% compared to the closing price of the day [2] - Institutional specialized seats participated in one of the trades, with a total transaction amount of 60.30 million yuan, indicating a net purchase of 60.30 million yuan [2] - Over the past three months, Yifang Bio-U has recorded a total of 44 block trades, amounting to 305 million yuan [2] Group 2 - On the same day, Yifang Bio-U closed at 35.22 yuan, up 0.40%, with a turnover rate of 5.99% and a total transaction volume of 853 million yuan, while the main capital outflow was 41.75 million yuan [2] - In the last five days, the stock has decreased by 12.71%, with a total capital outflow of 166 million yuan [2] - The latest margin financing balance for the stock is 17.70 million yuan, which has increased by 3.82 million yuan over the past five days, reflecting a growth rate of 27.50% [2]

Summary of Key Points Core Viewpoint - On September 11, 18 stocks from the STAR Market experienced block trading, with a total transaction amount of 926 million yuan, indicating active trading in the sector [2]. Trading Overview - A total of 37 block trades were executed, with a cumulative trading volume of 13.07 million shares [2]. - The stock with the highest transaction amount was Huatai Medical, with a trading volume of 2.16 million shares and a transaction amount of 537 million yuan [2]. - Other notable transactions included Dameng Data and Yifang Bio, with transaction amounts of 83.43 million yuan and 62.41 million yuan, respectively [2]. Price Discount Analysis - Among the stocks involved in block trading, the highest discount rates relative to the closing prices were observed in Hengxuan Technology, Yuntian Lifi, and Huatai Medical, with discount rates of 25.15%, 23.13%, and 19.81% respectively [2]. Stock Performance - The STAR 50 Index rose by 5.32% on the same day, with 524 stocks (89.12%) in the STAR Market experiencing price increases [2]. - The average increase for stocks involved in block trading was 3.72%, with Dameng Data, Cambrian, and Hengxuan Technology leading the gains at 9.19%, 8.96%, and 6.88% respectively [2]. - Conversely, Junshi Biosciences and Aters saw declines of 1.59% and 0.24% respectively [2]. Institutional Participation - Out of the block trades, 12 transactions involved institutional buyers or sellers, covering 9 stocks [3]. - The top three stocks by institutional buying amounts were Dameng Data (83.43 million yuan), Yifang Bio (60.30 million yuan), and Aters (50.81 million yuan) [3]. Fund Flow Analysis - Among the stocks involved in block trading, 9 stocks saw net inflows from major funds, with the highest net inflows recorded for Yuntian Lifi (207 million yuan), Cambrian (184 million yuan), and Dameng Data (105 million yuan) [3]. - The stocks with the highest net outflows included Junshi Biosciences (99.41 million yuan), Aters (87.10 million yuan), and Borui Pharmaceutical (56.94 million yuan) [3].

中信证券股份有限公司 关于益方生物科技（上海）股份有限公司 2025 半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为益方生 物科技（上海）股份有限公司（以下简称"益方生物"或"公司"或"上市公司"） 首次公开发行股票并在科创板上市的保荐人，根据《上市公司募集资金监管规则》 《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》等 相关规定，中信证券履行持续督导职责，并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间（指 2025 年 1-6 月，下同），保荐人通过与公司的日常 沟通、现场回访等方式开展持续督导工作。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、股东会和董事会议事规则等公司治理制度、股东会和 董事会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； ...

Group 1 - The core transaction involved 2.07 million shares of Yifang Bio, with a total transaction value of 62.41 million yuan, accounting for 6.82% of the total trading volume on that day [1] - The transaction price was 30.15 yuan per share, which represents a discount of 14.4% compared to the market closing price of 35.22 yuan [1] - The transaction occurred on September 11, 2025, indicating significant trading activity for Yifang Bio on that date [2] Group 2 - The transaction was executed through institutional channels, with specific involvement from Guangfa Securities and CITIC Securities [2] - The total transaction amount was broken down into 60.30 million yuan for one part and 2.11 million yuan for another, highlighting the scale of institutional interest [2] - The shares traded were part of a specialized institutional transaction, indicating a strategic move by institutional investors [2]

Group 1 - Yifang Biotechnology's stock increased by 5.22%, reaching 35.66 CNY per share, with a trading volume of 279 million CNY and a turnover rate of 1.89%, resulting in a total market capitalization of 20.623 billion CNY [1] - Yifang Biotechnology, established on January 11, 2013, and listed on July 25, 2022, is located in the China (Shanghai) Free Trade Zone and focuses on the research, production, and sales of innovative drugs, with 100% of its main business revenue coming from technology licensing and cooperation [1] Group 2 - Guolian Fund has a significant holding in Yifang Biotechnology, with its Guolian Medical Consumption Mixed A Fund (015032) reducing its stake by 71,100 shares in the second quarter, now holding 152,100 shares, which accounts for 5.93% of the fund's net value, making it the third-largest holding [2] - The Guolian Medical Consumption Mixed A Fund has achieved a year-to-date return of 61.78%, ranking 290 out of 8,177 in its category, and a one-year return of 83.58%, ranking 619 out of 7,982 [2]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company's D-2570 (TYK2) inhibitor shows potential as a best-in-class treatment, with ongoing clinical trials for multiple indications including ulcerative colitis and psoriasis [1][2] - D-2570 demonstrated superior efficacy in Phase II trials for psoriasis, achieving a PASI 75 response rate of 90.0%, significantly higher than the placebo group [1] - The safety profile of D-2570 is favorable, with most adverse events being mild to moderate and no serious adverse events reported [1] Clinical Development - D-2570 is being explored for various indications, including ulcerative colitis, psoriatic arthritis, and systemic lupus erythematosus [2] - The Phase II clinical trial for ulcerative colitis commenced in May 2025 [2] Preclinical Innovations - The company has high molecular innovation in preclinical candidates YF087 and YF550, which have shown excellent anti-tumor efficacy in various animal models [3][4] - YF087 targets the synthetic lethal target WRN, demonstrating significant effects on MSI-H tumors, while YF550 targets KIF18A, crucial for the proliferation of CIN+ tumor cells [3][4] Financial Forecast - The company is expected to face challenges in profitability, with projected net losses of -243 million and -219 million CNY for 2025 and 2026 respectively [5][10] - Revenue is forecasted to grow from 185.53 million CNY in 2023 to 503.37 million CNY by 2027, reflecting a compound annual growth rate [10][12] Market Position - The company operates in the highly competitive pharmaceutical and chemical manufacturing industry, particularly in the oncology and autoimmune disease segments [5]

Investment Rating - The investment rating for the company is "Accumulate" [3][6]. Core Insights - The company has demonstrated exceptional capabilities in innovative drug research and development, with a competitive product pipeline [2]. - For the first half of 2025, the company reported a revenue of 0.19 billion yuan, representing a 29% year-on-year increase, and a net loss attributable to shareholders of 1.19 billion yuan, which is a 44% reduction in loss compared to the previous year [1][2]. Summary by Sections Company Overview - The company focuses on target selection in areas with large patient populations and unmet clinical needs, enhancing development speed through international multi-center clinical trials [2]. Product Pipeline - The company has several advanced clinical pipeline products, including: - KRASG12C inhibitor, Goserelin, which is approved for non-small cell lung cancer and is expected to be used for colorectal cancer and other cancers, with a market approval anticipated in November 2024 [2]. - Oral SERD targeted drug D-0502, which offers better convenience and compliance compared to existing muscle injection SERDs, with a key phase III registration trial approved in October 2021 [2]. - D-2570, a novel oral selective inhibitor targeting TYK2 for treating psoriasis and other autoimmune diseases, has shown significant efficacy in clinical trials and is expected to provide new treatment options for patients [2]. Financial Forecast - The company maintains its revenue forecasts for 2025-2027, expecting total revenues of 2.00 billion yuan, 3.50 billion yuan, and 5.00 billion yuan respectively, with EPS of -0.35, -0.24, and -0.33 yuan for the same periods [3][6].